Search

Avian leukosis virus (ALV) is an enveloped retrovirus with a single-stranded RNA genome, belonging to the genus Alpharetrovirus within the family Retroviridae. The disease (Avian leukosis, AL) caused by ALV is mainly characterized by tumor development and immunosuppression in chickens, which increases susceptibility to other pathogens and leads to significant economic losses in the Chinese poultry industry. The government and poultry industry have made lots of efforts to eradicate ALV, but the threat of which remains not vanished. This review provides a summary of the updated understanding of ALV in China, which mainly focuses on genetic and molecular biology, epidemiology, and diagnostic methods. Additionally, promising antiviral agents and ALV eradication strategies performed in China are also included., Competing Interests: DISCLOSURES Author Juan Li was employed by Yunnan Sino-science Gene Technology Co., Ltd. The authors declare no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)

Control of ALV-J in breed of chicken is still a serious issue that need more attention to be paid. Vertical transmission of ALV-J often give rise to more adverse pathogenicity. However, the way to elimination of ALV-J underlying vertical transmission remains not-well understood. In addition, effective vaccines or drugs have not been developed to prevent and control the transmission of ALV-J so far. CD81, a member of the tetraspanins superfamily, plays important roles in regulating membrane proteins, facilitating cells adhesion or fusion, and also participates in viral infection. The purpose of this study was to investigate whether antibodies against certain tetraspanins affect infection of ALV-J. Here, we showed that anti-CD81 antibody could inhibit viral RNA and protein level. We also found that anti-CD81 antibody interacts with viral protein p27, p32 and gp37. Moreover, treatment with antibody to CD81 can effectively prevent the vertical transmission of ALV-J in animal model. Collectively, current study provides new avenues for the control of ALV-J transmission., (Copyright © 2021 Elsevier B.V. All rights reserved.)

Avian leukosis, caused by avian leukosis virus (ALV), is an infectious tumor disease and severely hinders the development of the poultry industry. The use of Lactobacillus plantarum (L. plantarum) could effectively alleviate viremia in the early period of J subgroup ALV (ALV-J) infection. In this study, an invasive L. plantarum NC8 expressing Gp85 protein of ALV-J was constructed. After chickens were orally administered the recombinant invasive NC8, the levels of expression of CD4 + and CD8 + T lymphocytes in peripheral blood and spleen by flow cytometry and the proliferation ability of splenocytes by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay were examined, and the contents of cytokines, the anti-ALV-J antibody in serum, and mucosal antibody sIgA in intestinal lavage fluid were detected by enzyme-linked immunosorbent assay (ELISA). The immunoprotective efficiency was evaluated by monitoring the infection rate, the percent of cloacal swabs and survival, body weight gain, the organ indexes, and relative virus loads after challenge with ALV-J. The results showed that the recombinant invasive strain (FnBPA-gp85) could promote the expression levels of the CD8 + T cells in peripheral blood and spleen, the proliferation of splenocytes, the secretions of cytokines interleukin 2 (IL-2) and γ-interferon (IFN-γ), and the production of IgG and sIgA compared with the PBS and FnBPA control groups in chickens. The FnBPA-gp85 group was exhibited the highest immune protection against ALV-J infection. The above results indicated that the recombinant invasive NC8 could promote the cellular immunity, humoral immunity, and mucosal immunity responses in chicken and provide a new method for exploring the live vaccine against ALV-J.Key points• The FnBPA-gp85 strain could enhance cellular immunity response.• The FnBPA-gp85 strain could improve the immune protection against ALV-J infection., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Based on the RNA-seq data of chicken spleen tissues infected with J subgroup avian leukosis virus (ALV-J), we found that prolactin (PRL) gene was one of differentially expressed gene. We measured ALV-J viremia and PRL levels in the plasma of two groups of ALV-J-infected adult chickens. Furthermore, recombinant chicken PRL (cPRL) was used to assess how cPRL affects ALV-J virus replication both in vivo and in vitro. The results showed that PRL levels in the plasma of adult chickens infected with ALV-J were lower than those of uninfected chickens, and that the difference was more significant in the avian leukemia pathological apparent changes. Notably, the fluctuations in PRL levels might influence the disappearance of ALV-J viremia in chickens. The in vitro results showed that preincubating DF-1 cells with cPRL before ALV-J infection elicited the best antiviral effects. Moreover, these effects were not dose-dependent. in vivo, injection of cPRL into ALV-J-infected chicks could reduce the levels of viremia at the 14 days post infection (dpi). Additionally, the expression of the interferon-stimulated genes oligoadenylate synthetase-like (OSAL) and vasoactive intestinal peptide (VIP) increased, and that of the proinflammatory cytokine-encoding TNTα, IL-1β, and IL-6 genes decreased in the spleens of ALV-J-infected chicks injected with cPRL, leading to inhibition of viral replication at the 7 dpi. Collectively, our data demonstrated that PRL plays an important antiviral role in the immune response to ALV-J infection. This is the first report of the relationship between ALV-J infection and PRL. It is of great significance for the prevention and control of ALV-J., (Copyright © 2021 Elsevier B.V. All rights reserved.)

Avian leukosis (AL) is one of the most pandemic immunosuppressive diseases and has been widely spread between 2006 and 2009 in China. The contamination of avian leukosis virus (ALV) in attenuated vaccine is considered as one of the possible transmission routes of this disease. Based on a retrospective survey of 918 batches of attenuated vaccine produced before 2010, three of them were identified as ALV-positive and corresponding ALV strains were successfully isolated from a live Fowlpox virus vaccine, a live Newcastle disease virus vaccine and a live Infectious Bursal Disease virus vaccine, respectively, and whole-genome sequencing showed that these three isolates shared the highest homology with ALV-A wild strains isolated in China (97.7%) over the same period, and the phylogenetic analysis based on their gp85 genes further confirmed that they belong to subgroup A. Meanwhile, although these three ALV-A strains isolated from contaminated vaccines shared a close genetic relationship, their U3 region of genome have a relatively low identity, suggesting that these three strains may have different sources. This study reminds us once again that the possibility of ALV infecting chickens through contaminated live vaccines, requiring us to carry out stricter exogenous virus monitoring in vaccines., Competing Interests: Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2020 Elsevier B.V. All rights reserved.)

The CRISPR/CRISPR-associated protein 9 (Cas9) system is a powerful gene-editing tool originally discovered as an integral mediator of bacterial adaptive immunity. Recently, this technology has been explored for its potential utility in providing new and unique treatments for viral infection. Marek's disease virus (MDV) and avian leukosis virus subgroup J (ALV-J), major immunosuppressive viruses, cause significant economic losses to the chicken industry. Here, we evaluated the efficacy of using MDV as a CRISPR/Cas9-delivery system to directly target and disrupt the reverse-transcribed products of the ALV-J RNA genome during its infection cycle in vitro and in vivo. We first screened multiple potential guide RNA (gRNA) target sites in the ALV-J genome and identified several optimized targets capable of effectively disrupting the latently integrated viral genome and providing efficient defense against new infection by ALV-J in cells. The optimal single-gRNAs and Cas9-expression cassettes were inserted into the genome of an MDV vaccine strain. The results indicated that engineered MDV stably expressing ALV-J-targeting CRISPR/Cas9 efficiently resisted ALV-J challenge in host cells. These findings demonstrated the CRISPR/Cas9 system as an effective treatment strategy against ALV-J infection. Furthermore, the results highlighted the potential of MDV as an effective delivery system for CRISPR/Cas9 in chickens., Competing Interests: Declaration of Competing Interest The authors declare that they have no competing interests., (Copyright © 2020 Elsevier B.V. All rights reserved.)

To evaluate whether carbon quantum dots (CQDs) can serve as an excellent adjuvant for the gp85 protein vaccine, this study produced recombinant gp85 protein against the avian leukosis virus subgroup J (ALV-J) in chickens. Functionalized CQDs were prepared and then linked to the recombinant gp85 protein. A total of 36 chickens were divided into 3 groups, namely, 2 experimental groups and 1 control group. Chickens from the experimental groups were inoculated twice intramuscularly with purified recombinant gp85 protein with CQDs as adjuvant or Freund's adjuvant emulsion at 14 and 21 D, whereas those from the control group were inoculated with an equivalent volume of PBS. At 35 D, the chickens were challenged with a 102.4 50% tissue culture infective dose of ALV-J. Blood samples were collected from each chicken at weekly intervals for serum antibody and viremia analyses. Results indicated that immunization with gp85-CQDs or gp85-Freund's adjuvant induced the inoculated chickens to produce positive serum antibodies (sample-to-positive ratio >0.6) at the 3rd week and persisted over 9 wk. Antibody levels in the gp85-CQDs group were higher than those in the gp85-Freund's adjuvant group. Differences were significant at 21 D (P < 0.05) and extremely significant from 28 D to 70 D (P < 0.01). Additionally, results of viremia showed higher protection in the gp85-CQDs group than in the Freund's adjuvant group. These findings highlighted the potential of CQDs as excellent candidate nanovehicles for vaccine delivery., (© 2019 Poultry Science Association Inc.)

In this study, a novel oral vaccine of recombinant Lactobacillus plantarum ( L. plantarum ) containing the gp85 protein was explored, and the effects of this vaccine on the prevention of subgroup J Avian Leukosis Virus (ALV-J) infection were assessed. In the current study, the gp85 protein of ALV-J was expressed on the surface of L. plantarum with the surface-display motif, pgsA , by constructing a shuttle vector pMG36e:pgsA:gp85 . Surface localization of the fusion protein was verified by western blotting and flow cytometry. Subsequently, Specific Pathogen Free Hy-Line Brown layer chickens were orally vaccinated with the recombinant L. plantarum and presented with high levels of serum immunoglobulin G (IgG) and secretory immunoglobulin A (sIgA) titers in bile and duodenal-mucosal fluid. After challenged with ALV-J of a 3 × 10 3 50% tissue culture infective dose (TCID50), serum samples of the chickens were collected and viremia was analyzed. Results showed that, compared to the L. plantarum and PBS control group, the recombinant L. plantarum group showed a significant rise in antibody levels after inoculation, and provide improved protection against ALV-J according to viremia detection. These results indicate that oral immunization with the recombinant L. plantarum provided an effective means for eliciting protective immune response against early ALV-J infection., (Copyright © 2019 Wang, Geng, Zhou, Qu, Shi, Xu, Liu, Liu and Liu.)

This study focuses on preparing the secretory recombinant J subgroup of avian leukosis virus (ALV-J) gp85 protein using Pichia pastoris and evaluating its immunoprotection as vaccine antigen combining with CpG-ODN adjuvant. The secretory recombinant plasmid pPIC9-gp85 containing ALV-J gp85 gene was designed and was transfected into the genome of P. pastoris (GS115) cells. The recombinant plasmid was expressed under the induction of methanol. The expressed products in the medium of the cells were purified and identified with endoglycosidase digestion assay and western blot mediated with monoclonal antibody (MAb) JE9. The purified product combining with CpG-ODN adjuvant was inoculated intramuscularly into 7-day-old chickens and three booster inoculations were performed on 21 days post first inoculation (dpfi), 42, and 56 dpfi. The antibody responses and cellular immune responses were detected, and the protective effects were analyzed after challenge with ALV-J. The results showed that the secretory pPIC9-gp85 plasmid was successfully constructed and could be stably expressed in GS115 cells. The expressed products were N-acetylglucosylated and could specifically combine with MAb (JE9). The secreted gp85 protein combining with CpG-ODN adjuvant could induce higher antibody response and spleen lymphocyte proliferation response and IFN-γ-inducing response, and could protect all the inoculated chickens against the viremia and the immunosuppressive lesions caused by ALV-J challenge. The results of neutralizing test in vitro suggested that the antisera with some ALV-J antibody titers could neutralize ALV-J strain and inhibit the growth of virus in vitro. The result of IFA showed that IgG antibody in the antisera could specifically combine with ALV-J strain in cells. It can be concluded that the secretory recombinant gp85 protein, as a new acetylglucosylated gp85 protein, was successfully prepared and combining with CpG-ODN adjuvant could protect the inoculated chickens against ALV-J infection. This study first reported the methods on preparing the secretory recombinant ALV-J gp85 protein using P. pastoris and evaluated its immunoprotection.

Avian leukosis virus subgroup J (ALV-J), an oncogenic retrovirus, induces myelocytomas and other various tumors, leading to great economical losses in poultry industry. It is a great challenge to develop effective preventive methods for ALV-J control due to its antigenic variations in the variable regions of envelope. In present study, we generated a mouse polyclonal antibody targeting the first extracellular loop (ECL1) of chicken Na + /H + exchanger isoform 1 (chNHE1), the receptor of ALV-J, to block ALV-J infection in vitro and in vivo. In ALV-J infected DF-1 cells, chNHE1 expression and the intracellular pH (pHi) were up-regulated with "wave" pattern, indicating that the disequilibrium of ALV-J infected cells associated with chNHE1. Next, we validated that ALV-J infection was significantly blocked with time dependent after treating with anti-ECL1 antibody and accordingly the pHi value were recovered, indicating the blockage of ALV-J infection did not affect Na + /H + exchange. Furthermore, in anti-ECL1 antibody treatment chickens that infected by ALV-J, weight gain and immune organs were recovered, and viral loads were significantly decreased, and the tissue injury and inflammation were reduced significantly from 21 to 35 days of age. The study demonstrated that anti-ECL1 antibody effectively blocks ALV-J infection without affecting Na + /H + exchange, and sheds light on a novel strategy for retroviruses control., (Copyright © 2018 Elsevier Ltd. All rights reserved.)

The hypervariable antigenicity and immunosuppressive features of avian leukosis virus subgroup J (ALV-J) has led to great challenges to develop effective vaccines. Epitope vaccine will be a perspective trend. Previously, we identified a variant antigenic neutralizing epitope in hypervariable region 1 (hr1) of ALV-J, N-LRDFIA/E/TKWKS/GDDL/HLIRPYVNQS-C. BLAST analysis showed that the mutation of A, E, T and H in this epitope cover 79% of all ALV-J strains. Base on this data, we designed a multi-variant epitope ensemble vaccine comprising the four mutation variants linked with glycine and serine. The recombinant multi-variant epitope gene was expressed in Escherichia coli BL21. The expressed protein of the variant multi-variant epitope gene can react with positive sera and monoclonal antibodies of ALV-J, while cannot react with ALV-J negative sera. The multi-variant epitope vaccine that conjugated Freund's adjuvant complete/incomplete showed high immunogenicity that reached the titer of 1:64,000 at 42 days post immunization and maintained the immune period for at least 126 days in SPF chickens. Further, we demonstrated that the antibody induced by the variant multi-variant ensemble epitope vaccine recognized and neutralized different ALV-J strains (NX0101, TA1, WS1, BZ1224 and BZ4). Protection experiment that was evaluated by clinical symptom, viral shedding, weight gain, gross and histopathology showed 100% chickens that inoculated the multi-epitope vaccine were well protected against ALV-J challenge. The result shows a promising multi-variant epitope ensemble vaccine against hypervariable viruses in animals., (Copyright © 2017 Elsevier Ltd. All rights reserved.)

To explore the antibody responses and protective effects induced by subgroup J avian leukosis virus (ALV-J) gp85 protein vaccine plus different adjuvants (CpG and white oil adjuvant YF01) combined with the immune enhancer Taishan Pinus massoniana pollen polysaccharide (TPPPS), we immunized SPF chickens with the recombinant ALV-J gp85 protein, along with different adjuvants and immune enhancer, which protected the chickens by inducing different levels of protective antibodies. Results showed that a single injection of gp85 recombinant protein could only produce low-titre antibodies that were maintained over a short time in few chickens. When combined with YF01 or CpG adjuvants, the recombinant protein could induce high-titre antibodies in most of the immunized chickens. Moreover, when the immune enhancer TPPPS was used with the two adjuvants, it further elevated the antibody levels for a longer duration. The eggs from four groups with the highest levels of ALV-J antibodies were collected, hatched, and examined for maternal antibodies. The protection by the maternal antibodies against ALV-J infection in the TPPPS-immunized group was higher than that in the group without TPPPS, which was consistent with the observations in the parents. This study shows that the immune enhancer TPPPS, combined with YF01 or CpG adjuvants, can enhance the immunogenicity of gp85 recombinant proteins, and provide a better immuno-protection. It provides a powerful experimental basis for the development of ALV-J subunit vaccine. Efficient subunit vaccine development will also accelerate the process of purification of ALV-J., (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Subgroup J avian leucosis virus (ALV-J) generally causes neoplastic diseases, immunosuppression and subsequently increases susceptibility to secondary infection in birds. The spread of ALV-J mainly depends on congenital infection and horizontal contact. Although ALV-J infection causes enormous losses yearly in the poultry industry worldwide, effective measures to control ALV-J remain lacking. In this study, we demonstrated that Taishan Pinus massoniana pollen polysaccharide (TPPPS), a natural polysaccharide extracted from Taishan Pinus massoniana pollen, can significantly inhibit ALV-J replication in vitro by blocking viral adsorption to host cells. Electron microscopy and blocking ELISA tests revealed that TPPPS possibly blocks viral adsorption to host cells by interacting with the glycoprotein 85 protein of ALV-J. Furthermore, we artificially established a congenitally ALV-J-infected chicken model to examine the anti-viral effects of TPPPS in vivo. TPPPS significantly inhibited viral shedding and viral loads in immune organs and largely eliminated the immunosuppression caused by congenital ALV-J infection. Additionally, pre-administration of TPPPS obviously reduced the size and delayed the occurrence of tumors induced by acute oncogenic ALV-J infection. This study revealed the prominent effects and feasible mechanisms of TPPPS in inhibiting ALV-J infection, thereby providing a novel prospect to control ALV-J spread.

Infection with the avian leukosis virus subgroup J (ALV-J) can lead to neoplastic disease in chickens, inflicting significant economic losses to the poultry industry. Recent reports have identified inhibitory effects of ALV-J on autophagy, a process involving in innate and adaptive immunity. Inspired by this connection between autophagy and immunity, we developed a novel DNA vaccine against ALV-J which includes co-administration of rapamycin to stimulate autophagy. To measure the efficacy of the developed prototype vaccine, five experimental groups of seven-day-old chickens was immunized three times at three-week intervals respectively with vector, pVAX1-gp85, pVAX1-gp85-LC3, pVAX1-gp85+rapamycin and pVAX1-gp85-LC3+rapamycin through electroporation. We then tested their antibody titers, cytokine levels and cellular immune responses. The immunoprotective efficacy of the prototype vaccines against the challenge of the ALV-J GD1109 strain was also examined. The results showed that the combination of pVAX1-gp85-LC3 and rapamycin was able to induce the highest antibody titers, and enhance interleukin(IL)-2, IL-10 and interferon (IFN)-γ expression, and the chickens immunized with the combination of pVAX1-gp85-LC3 and rapamycin showed the highest percentage of CD3+CD8+T lymphocytes. Based on our results, we suggest that stimulating autophagy can improve the efficacy of DNA vaccines and that our DNA vaccine shows the potential of being a candidate vaccine against ALV-J. This study provides a novel strategy for developing vaccines against ALV-J., (Copyright © 2016 Elsevier Ltd. All rights reserved.)

This study focused on the effect of silica nanoparticles as adjuvant for vaccine applications comprised of gp85, a dominating structural protein of J Subgroup Avian Leukosis Virus (ALV-J), and which was evaluated by comparing with the responsiveness induced by that emulsified in Freund adjuvant. Thirty-six chickens were inoculated twice with gp85 adjuvanted with the silica nanoparticles or Freund's adjuvant at the 2nd and 3rd week old. Two weeks later, the inoculated chickens were challenged with a 10 2.2 50% tissue culture infective dose (TCID50) of ALV-J. The blood samples were collected weekly to detect the serum antibodies and viremia. Results showed that positive serum antibodies (S/P value>0.6) against gp85 emerged at the third week in the inoculated chickens, while the antibodies level persisted longer in silica nanoparticles adjuvanted-group to Freund's adjuvanted-group. Furthermore, viremia in silica nanoparticles adjuvanted-group was recovered more quickly compared with Freund's adjuvanted-group. Hence our study revealed that silica nanoparticles can effectively improve the protection of gp85 vaccine against ALV-J and present a better performance than Freund's adjuvant., (Copyright © 2016 Elsevier Ltd. All rights reserved.)

Avian leukosis virus subgroup J (ALV-J) is an immunosuppressive virus that causes considerable economic losses to the chicken industry in China. However, there is currently no effective vaccine to prevent ALV-J infection. In order to reduce the losses caused by ALV-J, we constructed two effective ALV-J vaccines by inserting the ALV-J (strain JL093-1) env or gag + env genes into the US2 gene of the Marek's disease herpesviruses (MDV) by transfection of overlapping fosmid DNAs, creating two recombinant MDVs, rMDV/ALV-gag+env and rMDV/ALV-env. Analysis of cultured chicken embryo fibroblasts infected with the rMDVs revealed that Env and Gag were successfully expressed and that there was no difference in growth kinetics in cells infected with rMDVs compared with that of cells infected with the parent MDV. Chickens vaccinated with either rMDV revealed that positive serum antibodies were induced. Both rMDVs also effectively reduced the rate of positive viremia in chicken flocks challenged with ALV-J. The protective effect provided by rMDV/ALV-env inoculation was slightly stronger than that provided by rMDV/ALV-gag+env. This represents the first study where a potential rMDV vaccine, expressing ALV-J antigenic genes, has been shown to be effective in the prevention of ALV-J. Our study also opens new avenues for the control of MDV and ALV-J co-infection., Competing Interests: The authors declare that they have no competing interests.

The prokaryotic expressed recombinant chimeric multi-epitope protein X (rCMEPX) had been evaluated with good immunogenicity and protective efficacy against subgroup J avian leukosis virus (ALV-J) in our previous study. In the present research, we cloned the chimeric multi-epitope gene X into the eukaryotic expression vector pVAX1 to evaluate its potency as a DNA vaccine. The purified recombinant gp85 protein and rCMEPX were used as positive controls and a DNA prime-protein boost strategy was also studied. Six experimental groups of 7-day-old chickens (20 per group) were immunized intramuscularly three times at 2weeks interval with PBS, gp85, rCMEPX, pVAX1, pVAX-X and pVAX-X+rCMEPX respectively. The antibody titers and cellular immune responses were assayed after immunization. The efficacy of immunoprotection against the challenge of ALV-J NX0101 strain was also examined. The results showed that the DNA vaccine could elicit both neutralizing antibodies and cellular responses. Immune-challenge experiments showed good protection efficacy against ALV-J infection. Particularly, the regimen involving one priming pVAX-X and twice recombinant rCMEPX boosting, induced the highest antibody titers in all immunized groups. Our results suggest that the constructed chimeric multi-epitope DNA has potential for a candidate vaccine against ALV-J when used in proper prime-boost combinations. The data presented here may provide an alternative strategy for vaccine design in chicken ALV-J prevention., (Copyright © 2016 Elsevier Ltd. All rights reserved.)

The intricate sequence and antigenic variability of avian leukosis virus subgroup J (ALV-J) have led to unprecedented difficulties in the development of vaccines. Much experimental evidence demonstrates that ALV-J mutants have caused immune evasion and pose a challenge for traditional efforts to develop effective vaccines. To investigate the potential of a multi-epitope vaccination strategy to prevent chickens against ALV-J infections, a recombinant chimeric multi-epitope protein X (rCMEPX) containing both immunodominant B and T epitope concentrated domains selected from the major structural protein of ALV-J using bioinformatics approach was expressed in Escherichia coli Rosetta (DE3). Its immunogenicity and protective efficacy was studied in chickens. The results showed that rCMEPX could elicit neutralizing antibodies and cellular responses, and antibodies induced by rCMEPX could specifically recognize host cell naturally expressed ALV-J proteins, which indicated that the rCMEPX is a good immunogen. Challenge experiments showed 80% chickens that received rCMEPX were well protected against ALV-J challenge. This is the first report of a chimeric multi-epitope protein as a potential immunogen against ALV-J., (Copyright © 2015 Elsevier B.V. All rights reserved.)

To observe the antibody responses induced by recombinant A subgroup avian leukosis virus (ALV-A) gp85 protein vaccine plus CpG-ODN adjuvant and the protection of maternal antibodies (MAbs) for the hatched chickens against early infection, the gp85 gene was amplified from the proviral cDNA of ALV-A-SDAU09C1 strain using PCR and the recombinant plasmid containing target gene was constructed and expressed in EscherichiaColi. The expressed product was confirmed using SDS-PAGE and western blot that it is about 46KD of recombinant protein. The purified recombinant proteins combining with CpG-ODN adjuvant or Freund's adjuvant were inoculated into the breeder hens, the ALV-A antibodies in serum and in egg-yolk were detected; the fertilized eggs from the vaccinated hens with different titers of egg-yolk antibody were hatched and then challenged with 10(4.2)/0.1mL TCID50 of ALV-A-SDAU09C1 strain, all the hatched chickens were weekly detected for the viremias and the cloacal swab P27 antigen and pathological lesions; the neutralizing test of antisera in vitro was conducted. The results showed that the recombinant gp85 proteins combining with CpG-ODN adjuvant could induce the breeder hens to produce better antibody responses than gp85 protein with Freund's adjuvant or without adjuvant; the MAbs with higher titers induced by CpG-ODN+gp85 proteins could obviously decrease the ratios of viremias (13% vs 33%), cloacal detoxification (20% vs 67%) and death (0% vs 22%) caused by ALV-A infection than those by gp85 protein without adjuvant. The results of the neutralizing test indicated that the antisera from the hatched chickens could neutralize the ALV-A-SDAU09C1 strain in vitro, but which depends on the antibody titers. The results of IFA confirmed that the serum antibody could combine with the ALV in DF1 cells. It can be concluded that the prepared ALV-A gp85 subunit vaccine combining with CpG-ODN adjuvant could induce the breeder hens to produce better neutralizing antibody responses and protect 80% of their offspring chickens against early infection., (Copyright © 2015 Elsevier B.V. All rights reserved.)

Background: The diseases caused by avian leukosis virus subgroup J (ALV-J) has become a serious problem in the poultry. Due to largely ineffective vaccines, new control measures are needed to be developed. RNA interference (RNAi) has been developed a promising measure for antivirus in poultry., Methods: In this study, miRNA-embedded siRNA interference was designed and used to inhibit ALV-J replication in vitro and in vivo. Each sequence of target siRNA derived from the gag (p15), pol (p32), env (gp85) and LTR (U3) gene of ALV-J was embedded into mouse miR-155 backbone as a pre-miRNA hairpin oligonucleotide sequence. After annealing, they were cloned into pcDNA6.2-GW/EmGFP-miR vector, respectively. For detecting the interference effect, recombinant vectors were introduced into DF-1 cells and day-old SPF chickens that infected with ALV-J., Results: In vitro, single target interference showed effective inhibition of reducing 74% ~ 85% mRNA of ALV-J. Double targets showed more efficient inhibition of reducing 96% ~ 98% mRNA of ALV-J. In vivo, chicks were inoculated with each recombinant plasmid in peritoneal cavity at day of hatch, and monitored infection status at interval 1 day postinfection for 4 weeks. Delivery of single target or double targets miRNA significantly reduced viremia and pathogenicity caused by ALV-J in vivo, especially the double targets., Conclusions: These data demonstrated that the miRNA-embedded siRNA interference is an efficient method for inhibition of ALV-J replication, especially double targets.

To identify if any exogenous avian leukosis virus (ALV) exists in a live vaccine of poultry according to the directives of the Ministry of Agriculture of the People's Republic of China, a live vaccine strain of the Newcastle disease virus (NDV) was neutralized using an anti-NDV antibody, and was subsequently used to inoculate DF-1 cells to investigate the presence of exogenous ALV. The DF-1 cells were cultured for 21 d and subsequently screened using an ELISA for the p27 antigen of the ALV. An exogenous ALV, designated ALV-NDVP4, was identified. The nucleotide sequence of the gp85 gene of the ALV-NDVP4 was compared with those of the various subgroups of the ALV. The amino acid sequence identities for the predicted gp85 of the ALV-NDVP4 and those of the ALV reference strains ranged from 88.2 to 99.5% for the 12 of the subgroup A strains of ALV (ALV-A) and from 82.7 to 87.4% for the B, C, D, and E subgroup strains. The amino acid sequence identities for the gp85 of the ALV-NDVP4 and those of the subgroup J reference strains ranged from 48.7 to 49.9%. The ALV-NDVP4 shared the highest level of homology with the SDAU09C3 strain of ALV-A, which was isolated in China, suggesting a common origin. This is the first report of ALV-A contamination in a live vaccine for poultry in China. Our findings highlight the need for improved monitoring methods for poultry vaccine production., (© 2014 Poultry Science Association Inc.)

To study the potential of liposome vaccines in the clinical prevention of ALV-J, the effect of recombinant gp85 protein of subgroup J avian leukosis virus (ALV-J) entrapped by liposomes in chickens against ALV-J infection was investigated in this paper. A recombinant plasmid (PET28a-gp85) containing the PET28a vector and gp85 gene was constructed and then expressed in Rosetta (DE3) cells with 0.5mM IPTG to produce recombinant gp85 proteins that could be entrapped by liposomes through reverse-phase evaporation. The chickens were inoculated intramuscularly either once or twice with the liposomes or with Freund's adjuvant emulsion containing recombinant gp85 protein. Sixty chickens were raised to one week old for the first inoculation and to three weeks old for the second inoculation. Chickens raised to five weeks old were challenged with a 10(2.4) 50% tissue culture infective dose (TCID50) of ALV-J. Blood samples were collected from each chicken at weekly intervals for serum antibody and viremia analyses. Changes in serum antibodies showed that positive serum antibodies (S/P value >0.6) could be induced in all groups regardless of the frequency of inoculation but improved significantly in the twice-inoculated groups. As well, high levels of antibodies emerged earlier in the Freund's adjuvant groups but persisted longer in the liposome groups. Detection of viremia indicated that the liposomes provide better protection against ALV-J than Freund's adjuvant emulsion and that this protection is directly influenced by serum antibody levels. Overall, this study reveals the potential of liposome vaccines containing recombinant gp85 protein in the clinical prevention of ALV-J., (Copyright © 2014 Elsevier Ltd. All rights reserved.)

In this study, the efficacy of a recombinant protein vaccine encoding the gp85 gene from the subgroup J avian leukosis virus (ALV-J) co-administered with cytosine-phosphate-guanine oligodeoxynucleotide (CpG-ODN) or Freund's adjuvants was investigated for the protection against early ALV-J infection in chickens. The gp85 gene from ALV-J was amplified using polymerase chain reaction (PCR), and the recombinant protein was expressed in Escherichia coli. The purified recombinant protein was injected intramuscularly into the breeder hens along with CpG-ODN or Freund's adjuvants, and the antibodies in the serum were assayed regularly post inoculation. The fertilized eggs from the vaccinated hens were hatched, the hatched chickens were challenged with 10(2.2) 50% tissue culture infective dose (TCID50) ALV-J on 1 day, and the maternal antibodies in the hatched chickens were examined regularly before and after the challenge. The viremia was determined weekly, and a histopathological analysis of the immunosuppressive lesions was performed. The results suggest that the gp85 recombinant protein was successfully prepared and was inoculated with CpG-ODN adjuvant into breeder hens to induce serological antibody against ALV-J in the hens and in the hatched chickens. The positive maternal antibodies in the hatched chickens provided effective protection for most chickens against viremia and dramatically decreased the number of immunosuppressive lesions; these protective effects were better than those of the gp85 recombinant protein plus Freund's adjuvant. The data will provide a scientific basis for the application of the ALV-J subunit vaccine to control ALV-J infection in chicken flocks., (Copyright © 2013 Elsevier Ltd. All rights reserved.)

Objectives: To develop an inactivated vaccine against subgroup B avian leukosis virus (ALV-B) and determine if vaccination of chicken breeders could protect young chicks from ALV-B horizontal infection at early stage and accelerate eradication progress., Methods: Chicken embryo fibroblast (CEF) cells were inoculated with SDAU09C2 strain of ALV-B and ALV-CEF was inactivated for preparation of oil-adjuvant vaccine. Eggs were collected from un-vaccinated and 9 vaccinated great parent female chickens for incubation. 1-day-old chicks were bled for testing their maternal antibodies to ALV-A/B and then inoculated with ALV-B. Viremia and cloaca p27 detection dynamics were tested and compared between chick groups with or without maternal antibody to ALV., Results: In 3 weeks after 3 vaccination with the inactivated vaccine, all 9 vaccinated breeders developed high antibody titers against ALV-A/B with ELISA read values of 1.69-1.89 (the positive base line was 0.4) and kept at the high titers for at least another 4 weeks. Maternal antibody was detected in 70% (12/17) of chicks from breeders with high antibody titers to ALV-A/B. Only 4 of 12 chickens with maternal antibodies developed temporary viremia and no viremia was detected in the left 8 maternal antibody positive chickens during the whole 14 week after inoculation of ALV-B at 1 day of age. But the persistent viremia was detected in 2-8 weeks in all 9 maternal antibody negative chickens and the viremia persisted in the whole tested period of 14 weeks after inoculation of ALV-B., Conclusions: The inactivated ALV-B vaccine could induce high titer antibody reaction to ALV-B, it could provide maternal antibodies to 1-day-old chickens and protect chickens from early infection of ALV-B., (Copyright © 2013 Elsevier Ltd. All rights reserved.)

The genome of nearly all chickens contains various DNA proviral insertions of retroviruses of subgroup E avian leukosis virus (ALVE). However, the elimination or control of ALVE gene expression is desirable to improve productivity, to improve resistance to avian leukosis virus (ALV)-induced tumours, and to develop safer live virus vaccines in chick embryos and cultured chick cells. Restriction fragment length polymorphism and polymerase chain reaction methods are used to define the presence of ALVE genes; and the expression of ALVE in chicken plasma or on cells, and the susceptibility of cells to ALVE is determined by flow cytometry using a specific (R2) antibody. ADOL line 0 chickens have been selected to be free of ALVE genes, while being resistant (i.e. lack receptors to ALVE), but susceptible to exogenous ALV (i.e. ALVA, ALVB, ALVC and ALVJ). To develop improved line 0-type chickens, ADOL line 0 was outcrossed to a commercial line that had one ALVE gene and evidence for ALVE resistance. Rous sarcoma virus (RSV) challenge was used to confirm resistance of F1 chickens to ALVE, and susceptibility of F2 breeders to ALVA and ALVB using test chicks produced by matings to line 7(2). Selected F2 breeders were resistant to ALVE, but susceptible to exogenous ALVA, ALVB, ALVC and ALVJ, based on challenge tests of progeny chick cells using an enzyme-linked immunosorbent assay. The new line, 0(1), has evidence for improved egg size, productivity, fertility and hatchability. Similar procedures may be used for development of productive ALVE free chicken lines with preferred ALV susceptibility traits.

The effects of avian leukosis virus subgroup J (ALV-J) infection on meat-type chickens reared in a simulated commercial setting were evaluated. Each of three ALV-J isolates was evaluated with both simulated horizontal transmission (SHT) and simulated vertical transmission (SVT). Mortality, morbidity, disease condemnations, and feed conversions were increased and body weights at processing were decreased in ALV-J infected birds as compared to sham inoculated hatch mates. The adverse effects of ALV-J infection were more severe in birds exposed by SVT than in birds exposed by SHT. At 8 weeks of age response to vaccination for infectious bronchitis virus and Newcastle disease virus or prior exposure to a pathogenic reovirus was assessed in the ALV-J and sham inoculated broiler chickens by challenge studies. Although not statistically significant, an overall trend of decreased protection to challenge after vaccination, or prior exposure, was observed in the ALV-J inoculates as compared to sham inoculated hatch mates. Differences in vaccine response were most evident in groups inoculated with ALV-J by the SVT route.

The commercially important neoplastic diseases of poultry are Marek's disease, which is caused by a herpesvirus, and the avian leukoses and reticuloendotheliosis, which are caused by retroviruses. These diseases are responsible for economic loss due to both mortality and depressed performance. Marek's disease virus (MDV) and avian leukosis viruses (ALVs) are prevalent throughout the world, and new strains which arise in particular locations may spread across borders, thereby undermining national disease control measures. Reticuloendotheliosis virus (REV) is also present in many countries. Marek's disease virus is transmitted horizontally only, and international spread in hatching eggs and day-old chicks can be prevented by appropriate hygiene precautions. Transmission of ALV and REV occurs both horizontally and vertically (through the egg), and measures to prevent international spread are more demanding. Marek's disease is controlled by vaccination, whilst avian leukosis is controlled by virus eradication programmes, mainly at the primary breeding level. Similar virus control measures can be applied for reticuloendotheliosis if necessary. No strong evidence exists to suggest that these avian tumour viruses constitute a danger to public health.

The ALVA11 germline insert in chickens is a defective subgroup A avian leukosis virus (ALV) proviral insert that expresses a low-to-moderate level of subgroup A ALV envelope glycoprotein. Chicks carrying or lacking ALVA11 were evaluated for response to challenge by RPL-42, a pathogenic field strain of subgroup A ALV, by either exposure to chicks shedding RPL-42 or direct injection with various doses of RPL-42. Chicks carrying ALVA11 were significantly more resistant, as measured by infectious virus and viral antibody status, to horizontal infection and direct injection of RPL-42 than chicks lacking ALVA11.

Marek's disease (MD) and lymphoid leukosis (LL) are two distinct viral diseases that cause tumor mortality in chickens. Marek's disease, being horizontally transmitted, is controlled through biosecurity measures and vaccination. Prevention of early exposure before vaccine immunity is established is most important. Some multi-house growing farms have converted to all single-age placements to break the ongoing cycle of transmission. Vaccination against MD involves either in ovo or day-old administration of live vaccine, including single or multiple serotype products. Field viruses appear to adapt over time and become resistant to the prevalent vaccine. The Rispens vaccine (CVI-988) has shown good efficacy against recently emerging very virulent MD strains in the U.S. Genetic resistance of the host to MD and control of other immunosuppressive diseases also affects MD susceptibility. Lymphoid leukosis is primarily vertically transmitted and therefore controlled by elimination of shedder hens at the primary breeder level. Depending upon the genetic type, commercial performance of laying hens may be greatly improved by eradication of the LL virus from the breeding stock.

Viral infections which are immunosuppressive can affect the economics of poultry production, often as a result of the chicken's increased susceptibility to secondary infections and sub-optimal response to vaccinations. The mechanism of this immunosuppression has been studied in detail for certain chicken viruses. The replicating virus can have both direct and indirect effects on the cells of the immune system. The special role of the bursa of Fabricius, as a lympho-epithelial organ, will be mentioned. The effects of oncogenic viruses (MDV, REV and ALV) on the immune system will be discussed as will the present status of our knowledge on the immunosuppressive effects of certain respiratory viruses such as ILT, NDV and reovirus. Two major immunosuppressive agents are CAV and IBDV. The effects of IBDV will be described in more detail because of its economic importance. Advances made in the molecular biology of both the virus and the immune system give new opportunities to control the disease by vaccination. Successful vaccination strategies applied in the past and options for the future will be discussed.

A recombinant fowlpox virus (FPV) was constructed by inserting cloned sequences from Schmidt-Ruppin subgroup A avian sarcoma virus coding for the viral envelope (env) antigen into a nonessential region of FPV DNA downstream from a synthetic promoter. Sera from chickens hyperimmunized with the recombinant FPV neutralized the infectivity of the homologous subgroup A virus (RCASBP/AP) but only weakly neutralized the infectivity of Rous sarcoma virus, another subgroup A avian leukosis virus. Similarly, vaccination of 1-day-old chicks with this recombinant FPV protected against infection with RCASBP/AP virus but not against infection with another subgroup A Rous-associated virus (RAV-1). These results show that such a recombinant FPV can be used to protect chickens against avian leukosis virus and confirm previous observations that a type-specific antigenic variability existed within the subgroup A avian leukosis/sarcoma virus group.

The biological costs of the alv6 recombinant transgene that in chickens induces dominant resistance to the subgroup A avian leukosis virus (ALV), in terms of effects on production traits, were studied. Four generations of White Leghorn chickens of Line TR, segregating for alv6 but free of endogenous viral genes, as well as two generations of crosses between TR and Ottawa Line WG (WGTR) were tested under a specific-pathogen-free environment. In the birds studied, the transgene appeared unchanged compared to the original alv6: No major changes in alv6 DNA were detected by restriction analysis, the transgene did not express the group-specific antigen of ALV, and its presence was associated with absence of immune response to ALV. In most test years, and both TR and WGTR genomic backgrounds, alv6 was associated with delayed sexual maturity by 4 to 6 d, reduced egg production to 497 d of age by 20 to 46 eggs, and a 3.6 to 15% decline in egg production rate. No consistent effects on other traits, including mortality, were detected. When inoculated with the AC-1 isolate of Marek's disease virus in a separate experiment, TR birds with alv6 had a significantly lower body weight gain to 10 d of age than their sibs without the transgene. Thus, transgenesis has biological costs that have to be assessed against desirable effects of transgenes.

A major mode of transmission of avian leukosis virus (ALV) is from a dam that is viremic with and immunologically tolerant to ALV, through the egg to the progeny. The authors have produced a line of chickens transgenic for a defective ALV provirus that expresses envelope glycoprotein, but not infectious virus, and is very resistant to infection with Subgroup A ALV. In the present experiment the authors sought to prevent or reduce congenital transmission by mating viremic-tolerant hens to males carrying the inserted provirus, thus introducing a gene for resistance into the progeny. Mature viremic females were mated with males hemizygous for the transgene to produce over 80 progeny each with and without the transgene. The chicks were hatched and maintained for 36 wk and observed for viremia, antibody, and the incidence of bursal lymphomas. Over 90% of the transgene-negative controls remained viremic through 36 wk of age and 51% developed bursal lymphomas. In contrast, 27% of the transgene-positive birds remained viremic and 18% died with bursal lymphomas. Thus, expression of Subgroup A envelope protein in the developing embryo reduced but did not eliminate congenital infection.

Infection by exogenous avian leukosis viruses (ALVs) causes economic loss from neoplastic mortality and from impaired performance of subclinically infected chickens. This paper reviews progress in research related to natural infection and its control. Subgroup A ALVs causing lymphoid leukosis are the most common viruses in the field, but variant viruses can arise and cause losses. In Israel in recent years, epidemic outbreaks of haemangiosarcomas caused by a virus of unusual cytopathogenicity have occurred. In the UK, an ALV belonging to a new subgroup for chickens has been recently isolated; this virus is able to cause myeloid leukosis and nephromas. ALV infection of commercial stock is controlled by virus eradication schemes that prevent vertical transmission of ALV from one generation to the next. In this regard, endogenous leukosis viruses and ev loci, notably ev21 linked to the K slow-feathering gene, have been shown to have a detrimental influence on responses to infection by exogenous ALVs, and on the success of eradication schemes. Tolerogenic properties of the ev loci are involved. Attention has also been directed to whether ev loci have any direct influence on performance traits. Although eradication provides the main means of controlling ALV, the development of transgenic techniques in chickens has renewed interest in genetic resistance, and some progress has also been made in developing recombinant vaccines.

The development of transgenic technology in poultry has lagged behind that in mammals because of the unique reproductive system of birds. Therefore, we chose to use wild-type and recombinant replication-competent avian leukosis viruses to determine whether these retroviruses could be artificially introduced into the germ line by injecting them near the blastoderm of fertile eggs just before incubation. We generated 23 proviral inserts that were stably inherited through two generations. Twenty-one inserts coded for complete avian leukosis virus. Two interesting inserts failed to produce complete virus. One coded for envelope glycoprotein only and the other coded for the group-specific antigen and envelope glycoprotein. Cell culture and animal studies showed that one of these inserts was very resistant to infection and oncogenesis by subgroup A field strains of avian leukosis virus. Therefore, this represents a model system for introducing genes from the pathogen into the host to induce host resistance to the pathogen. Future studies should be aimed at developing more efficient systems for introducing replication-defective retroviral vectors or cloned DNA into the germ line of poultry so that the regulation of gene expression can be studied and transgenic technology can be applied to the improvement of this highly reproductive group of farm animals.

1. A total of 3236 females from eight meat-type strains, half of which were vaccinated for Marek's disease (MD), and 11,193 Leghorn females from ten strains, all vaccinated for MD, were adventitiously exposed to MD and lymphoid leukosis (LL) viruses and observed to 392 and 497 d of age, respectively. 2. In the meat-type birds, vaccination reduced total mortality from 43-4% to 27-1% and mortality due to MD from 16-4% to 5-4% but did not affect mortality and LL (2-9% and 3-4%). 3. In the vaccinated Leghorns total mortality was 11%, including 2-1% from MD and 1-2% from LL. 4. Significant differences between strains of chickens were found in total mortality, as well as in MD and LL mortality. 5. Strain by vaccination interaction was observed in total rearing and adult mortality, as well as in the MD mortality of adult meat-type females. 6. Leghorn strains with higher rate of egg production and meat-type strains with lower growth rate to have better viability.

Lymphoid leukosis (LL), a neoplasm of the bursa-dependent lymphoid cells of the chicken, was induced by Rous-associated virus-1 in susceptible chickens. Cyclophosphamide (CY), which destroyed the lymphoid elements of the bursa of Fabricius and abrogated humoral immunity, prevented LL. Concomitantly, osteopetorosis and other neoplasms increased. Transfer of bursa cells from chickens into CY-treated hatchmates restored immune competence. Birds whose B-cell functions were reconstituted died of LL and were less likely to die of osteopetrosis and other neoplasms than were CY-treated chicks. These results suggested that the bursa cell transferred into the CY-treated chicks were the target cells for lymphoid leukosis transformation.

Two trials were conducted to determine whether lymphoid leukosis virus (LLV) could be eradicated from chicken breeder stocks in one generation. Dams were selected as potentially virus-free parents on the basis of negative tests for virus in progeny embryos (trial 1) or in vaginal-cloacal swabs (VCS) (trial 2) of the dams. In trial 1, 8 of 12 groups of chickens hatched from selected breeders remained free of LLV infection through 36 weeks of life. In trial 2, VCS appeared to be more efficient in detecting possible shedder dams, and only 1 of 72 groups of chickens showed evidence of infection at 14 weeks after hatching. Within that positive group, a single chicken was shown to be the possible cause of the infection. The results show that eradication of LLV can be accomplished in one generation by: 1) virological examination of dams for shedding; 2) elimination of the shedder dams; and 3) small-group rearing of the progeny chicks.

Five groups of genetically susceptible chickens were inoculated at hatching with lymphoid leukosis virus; four of these were given infectious bursal viruses of varying virulence at 14 days of age and one group was not inoculated (control). All chickens in the control group developed evidence of lymphoid leukosis by 180 days. Two groups given relatively virulent bursal disease viruses, which destroyed bursal lymphoid cells, did not develop lymphoid leukosis. Treatment with avirulent vaccines had no visible effect on bursal morphology and did not significantly alter the incidence of lymphoid leukosis in two other groups, although the time of development was delayed. Results of our study show that viral-induced destruction of the bursa of Fabricius eliminates the development of lymphoid leukosis but that infection without bursal destruction has little effect on lymphoid leukosis.

Chickens and quails were immunized in parallel either i.v. or intramuscularly (i.m.) with lectin column-purified antigens from chick embryo cells that were transformed in vitro by avain sarcoma virus (ASV). After five to six injections, immunity of the animals was tested by challenge with ASV into the wing webs. Whereas tumor growth was inhibited after i.v. immunization with respect to incidence rate and time of tumor appearance, tumor growth was enhanced after i.m. injection. Animals that were injected with normal cell antigens served as controls. Spleen cells from only those animals that were immunized i.v. exerted a cytotoxic effect in vitro against ASV-transformed cells, whereas spleen cells from i.m. injected animals, in contrast, suppressed such cytotoxicity. The search for serum blocking or arming factors suggested that sera from i.m. injected animals block cellular cytotoxicity whereas sera from i.v. immunized animals render normal spleen cells cytotoxic (arming effect). The use of viruses from different subgroups and of antigens from gp85-lacking ASV-transformed cells indicates that immune effects were obtained against tumor cell surface antigens that differ from the antigen that is involved in virus neutralization (s-gp85).

The cupric and ferric complexes of isonicotinic acid hydrazide (INH) inhibit the DNA synthesis catalysed by avian myeloblastosis virus (AMV) reverse transcriptase. The inhibition was to the extent of 95% by 50 microM of cupric-INH complex and 55% by 100 microM of ferric-INH complex. These complexes have been found to bind preferentially to the enzyme than to the template-primer. Kinetic analysis showed that the cupric-INH complex is a non-competitive inhibitor with respect to dTTP. The time course of inhibition has revealed that the complexes are inhibitory even after the initiation of polynucleotide synthesis. In vivo toxicity studies in 1-day-old chicks have shown that the complexes are not toxic up to a concentration of 500 microgram per chick. Infection of the 1-day-old chicks with AMV pretreated with 150 microgram of either of the complexes prevented symptoms of leukemia due to virus inactivation.

Duplicate trials with mibolerone at a dose of 1 microng/g of diet for the first 49 days of age reduced the incidence of lymphoid leukosis (LL) significantly (P less than .005) in chickens inoculated as day-old chicks with Rous-associated virus type 1 (RAV-1). The incidence of LL was not reduced in virus-challenged chickens administered mibolerone at 4 microng per gram of diet during days 29 through 49 of age. The bursal lymphocytic follicles atrophied significantly with both the 1- and 4-microng doses; but, on the basis of histologic examination, atrophy was more complete with the 1-microng dose of mibolerone administered during the first 49 days of age. Mibolerone appears to prevent LL development by producing early bursal atrophy of key target cells. These data suggest that mibolerone orally administered at 1 microng/g of diet during the first 49 days of age appears to be useful for LL prophylaxis. Field trials are under way to assess the effectiveness of mibolerone under natural conditions.

Lymphoid leukosis (LL) was eliminated from 3 inbred lines of White Leghorn chickens that were temporarily kept in isolation. The method of control was based on three elements: 1) From an infected flock we selected hens that produced LL virus-free eggs. Pooled extracts from groups of embryos were tested for vertical virus transmission by the nonproducer cell activation test. 2) Only eggs from dams that did not congenitally shed virus to their embryos were used to produce progeny. The offspring were reared in isolation for 2 months (at which time the age-related resistance against tumor formation had developed sufficiently). 3) The birds were subsequently inoculated im with 10(5) mean tissue culture infective doses of LL viruses of subgroups A and B and transferred to a conventional chicken house. The controlled exposure provided immunity against LL virus infection in a highly infect environment. This procedure resulted in birds a) with no boservable LL, and b) producing LL virus-free eggs. To obtain flocks that had no LL and produced virus-free progeny, the procedure had to be repeated for at least two generations due to the intermittent virus excretion that often occurred.

A specific-pathogen-free pedigreed breeding population of White Leghorns was determined to be free of lymphoid leukosis subgroups (LL-A and LL-B) on the basis of the standard resistance-inducing factor (RIF) test of sera of individual birds. The fourth pedigreed generation (G-4) was the first to test free of viruses of both sub-groups. In three subsequent pedigreed generations (G-5 through G-7) no viremic birds were found. The RIF test of sera was also used to detect carriers infected with LL-A and LL-B in sample populations of commercial broiler, brown-egg layer, and other White Leghorn breeding lines. When only known nonviremic dams were used for reproduction, in only one instance were viremic birds detected in samples of their progeny in succeeding generations. Some implications for a virus-free breeding program are discussed.